In a recent breakthrough, researchers have developed a new method to predict a patient’s response to neoadjuvant chemotherapy (NAC) for breast cancer. This method leverages the power of artificial intelligence (AI) and combines information from ultrasound images and pathology slides.
NAC is a type of chemotherapy given before surgery to shrink tumors and improve surgical outcomes. However, not all patients respond equally well to NAC. This new AI-based approach has the potential to personalize cancer treatment by allowing doctors to identify patients who are more likely to benefit from NAC.
The study involved training deep learning models on data from over 400 patients with breast cancer. The models were trained to identify patterns in the ultrasound images and pathology slides associated with a complete response to NAC.
The researchers found that the AI models accurately predicted which patients would have a complete response to NAC, with an accuracy of over 80%. This is significantly higher than the accuracy of traditional methods for predicting response to NAC.
The ability to predict a patient’s response to NAC could significantly impact cancer treatment. For patients predicted to have a poor response to NAC, doctors may switch to a different treatment plan. This could help improve patient outcomes and reduce the side effects of chemotherapy.
The use of artificial intelligence in cancer treatment is a rapidly growing field. This study is a promising example of how AI can personalize cancer care and improve patient outcomes.
Related Content: Self-Imaging OCT: A Cost-Effective DR Detector